[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP3927417A4 - Methods to predict repeated dose toxicity using an integrated organ platform - Google Patents

Methods to predict repeated dose toxicity using an integrated organ platform Download PDF

Info

Publication number
EP3927417A4
EP3927417A4 EP20759516.6A EP20759516A EP3927417A4 EP 3927417 A4 EP3927417 A4 EP 3927417A4 EP 20759516 A EP20759516 A EP 20759516A EP 3927417 A4 EP3927417 A4 EP 3927417A4
Authority
EP
European Patent Office
Prior art keywords
predict
methods
repeated dose
dose toxicity
integrated organ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20759516.6A
Other languages
German (de)
French (fr)
Other versions
EP3927417A1 (en
Inventor
James Mckim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lifenet Health
Original Assignee
Iontox LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iontox LLC filed Critical Iontox LLC
Publication of EP3927417A1 publication Critical patent/EP3927417A1/en
Publication of EP3927417A4 publication Critical patent/EP3927417A4/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP20759516.6A 2019-02-19 2020-02-19 Methods to predict repeated dose toxicity using an integrated organ platform Pending EP3927417A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962807708P 2019-02-19 2019-02-19
PCT/US2020/018911 WO2020172337A1 (en) 2019-02-19 2020-02-19 Methods to predict repeated dose toxicity using an integrated organ platform

Publications (2)

Publication Number Publication Date
EP3927417A1 EP3927417A1 (en) 2021-12-29
EP3927417A4 true EP3927417A4 (en) 2022-11-16

Family

ID=72144457

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20759516.6A Pending EP3927417A4 (en) 2019-02-19 2020-02-19 Methods to predict repeated dose toxicity using an integrated organ platform

Country Status (2)

Country Link
EP (1) EP3927417A4 (en)
WO (1) WO2020172337A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065616A2 (en) * 2003-01-16 2004-08-05 The General Hospital Corporation Use of three-dimensional microfabricated tissue engineered systems for pharmacologic applications
WO2015142462A1 (en) * 2014-03-21 2015-09-24 Iontox, Llc Dynamic multi organ plate
EP3287521A1 (en) * 2016-08-25 2018-02-28 Philip Morris Products S.A. Cell culture

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101061213B (en) * 2004-05-19 2012-12-19 麻省理工学院 Perfused three-dimensional cell/tissue disease models
US8603806B2 (en) * 2005-11-02 2013-12-10 The Ohio State Universtiy Research Foundation Materials and methods for cell-based assays
US20130143230A1 (en) * 2011-12-02 2013-06-06 The Trustees Of The Stevens Institute Of Technology Microfluidic-based cell-culturing platform and method
WO2014018770A1 (en) * 2012-07-25 2014-01-30 The Charles Stark Draper Laboratory, Inc. Modular platform for multi-tissue integrated cell culture
US20180355298A1 (en) * 2014-12-15 2018-12-13 The Regents Of The University Of California Multi-organ cell culture system and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065616A2 (en) * 2003-01-16 2004-08-05 The General Hospital Corporation Use of three-dimensional microfabricated tissue engineered systems for pharmacologic applications
WO2015142462A1 (en) * 2014-03-21 2015-09-24 Iontox, Llc Dynamic multi organ plate
EP3287521A1 (en) * 2016-08-25 2018-02-28 Philip Morris Products S.A. Cell culture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020172337A1 *

Also Published As

Publication number Publication date
WO2020172337A1 (en) 2020-08-27
EP3927417A1 (en) 2021-12-29

Similar Documents

Publication Publication Date Title
EP3654675A4 (en) Train-ground integrated comprehensive analysis platform
EP3585433A4 (en) Therapeutic compositions and related methods for photoimmunotherapy
EP3697404A4 (en) Compositions and methods for broad-spectrum antiviral therapy
EP3713410A4 (en) Apparatus for perfusion of an excised organ
EP3895103A4 (en) Framework for generating risk evaluation models
EP4006818A4 (en) Simulator
EP4054867A4 (en) Amphibious platform vehicle-vessel
EP4125815A4 (en) Therapeutic compositions
EP3937762A4 (en) Population health platform
EP3792900A4 (en) Technique simulator
EP3960255A4 (en) Exercise equipment
EP3997632A4 (en) Rydberg exciton quantum simulator
EP3893225A4 (en) Cardiac simulator
EP3952399A4 (en) Method executable by user equipment
EP3977895B8 (en) Game equipment
IL288472A (en) Tetracyclic compounds as cdc7 inhibitors
EP3681517A4 (en) Methods for improving organ function in organ transplant patients
IL286434A (en) Nicorandil derivatives
EP3636271A4 (en) Therapeutic agent for dilated cardiomyopathy
IL283950A (en) Methods and compositions for producing cannabinoids
EP4045161A4 (en) Game platform
KR102368721B9 (en) Integrated platform including transapi
EP3927417A4 (en) Methods to predict repeated dose toxicity using an integrated organ platform
EP3803856A4 (en) Voice application platform
GB201813128D0 (en) Biliary organoids

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210917

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20221019

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20221013BHEP

Ipc: C12N 5/00 20060101ALI20221013BHEP

Ipc: C12M 1/34 20060101ALI20221013BHEP

Ipc: A61N 1/00 20060101AFI20221013BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LIFENET HEALTH